Stock Price, News, Quote and Profile of HILLEVAX INC(NASDAQ:HLVX) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

HILLEVAX INC

NASDAQ:HLVX (9/6/2024, 8:19:24 PM)

After market: 1.71 -0.03 (-1.72%)

1.74

0 (0%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month-90.55%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap86.62M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 90 full-time employees. The company went IPO on 2022-04-29. The firm's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The firm's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.

Company Info

HILLEVAX INC

321 Harrison Ave, Suite 500

Boston MASSACHUSETTS

P: 16172135054

Employees: 90

Website: https://www.hillevax.com/

HLVX News

a month ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ: HLVX). Such investors are...

a month ago - InvestorPlaceHLVX Stock Earnings: HilleVax Misses EPS for Q2 2024

HLVX stock results show that HilleVax missed analyst estimates for earnings per share the second quarter of 2024.

a month ago - HilleVax, Inc.HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of...